<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660722</url>
  </required_header>
  <id_info>
    <org_study_id>1708212</org_study_id>
    <secondary_id>2018-001358-84</secondary_id>
    <nct_id>NCT03660722</nct_id>
  </id_info>
  <brief_title>Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects</brief_title>
  <acronym>BIGGER</acronym>
  <official_title>Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects Commencing Antiretroviral Therapy: the BIGgeR Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Co-morbidities, including low bone mineral density, increased visceral adiposity and chronic
      kidney disease (CKD) are frequent in people living with HIV, and may be driven by ongoing
      inflammation and immune activation. Initiation of ART reduces inflammation and immune
      activation and is associated with changes in bone and renal biomarkers and gut microbiota.
      Investigators hypothesise that changes in gut microbiome when starting antiretroviral therapy
      correlate to changes in bone and renal biomarkers and wish to explore possible mechanisms
      linking these by investigating changes in markers of inflammation and immune activation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>faecal microbial alpha-diversity</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Change in faecal microbial alpha-diversity (change in mean Shannon Diversity Index score in faecal microbiota) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>markers of gut epithelium integrity</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Change in markers of gut epithelium integrity and bacterial translocation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory marker</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change in inflammatory marker (c-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating markers of monocyte activation</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change in circulating marker of monocyte activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal glomerular biomarkers</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change in renal glomerular biomarker (KIM-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone biomarkers</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change in bone biomarkers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>HIV Positive</condition>
  <arm_group>
    <arm_group_label>Blood and urinary sample</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood and urinary sample in HIV 1 positive adults initiating treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood and urinary samples</intervention_name>
    <description>blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks</description>
    <arm_group_label>Blood and urinary sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 positive

          -  Age 18-64 years

          -  Able to give informed consent

          -  Not previously treated for chronic HIV-1 infection, except for pre- or post- exposure
             prophylaxis exposure or treatment for mother to child transmission &gt;12 months ago

          -  Due to commence antiretroviral therapy by treating clinician

        Exclusion Criteria:

          -  - Previous major intestinal surgery/inflammatory bowel conditions

          -  Infective diarrhoea in the last 3 months

          -  BMI&lt;18.5

          -  Currently pregnant OR planning to conceive during the study period

          -  Previous use of antiretroviral therapy, except for pre- or post- exposure prophylaxis
             exposure or treatment for mother to child transmission &gt;12 months ago

          -  Use of antibiotics (except for prophylactic co-trimoxazole) within the last 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amandine GAGNEUX-BRUNON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carine LABRUYERE, CRA</last_name>
    <phone>0477120764</phone>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amandine GAGNEUX-BRUNON, MD</last_name>
    <phone>0477120764</phone>
    <email>Amandine.Gagneux-Brunon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amandine GAGNEUX-BRUNON, MD</last_name>
      <email>Amandine.Gagneux-Brunon@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Amandine GAGNEUX-BRUNON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

